Alpha Tau Medical 8/18/2026 Earnings Report

Alpha Tau Medical EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.14
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Alpha Tau Medical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.14 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Alpha Tau Medical Announcement Details

• Date: 8/18/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Alpha Tau Medical (NASDAQ:DRTSW) is a clinical-stage medical technology company focused on the development of alpha-emitting radiation therapy for the treatment of solid tumor cancers. The company’s proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform leverages the short-range, high-energy alpha particles emitted by radium-224 to penetrate tumor tissues more effectively than conventional external-beam radiation. By implanting thin, needle-like sources directly into a tumor, Alpha DaRT delivers concentrated doses of radiation to malignant cells while sparing surrounding healthy tissue.

The Alpha DaRT technology is designed to enhance local tumor control in a variety of solid tumors, including head and neck, breast, skin, and pancreatic cancers. The minimally invasive procedure enables outpatient treatment sessions and can be combined with other modalities such as surgery, chemotherapy, and immunotherapy. Preclinical studies and early-phase clinical trials in Europe have demonstrated promising safety profiles and preliminary efficacy, supporting the continued advancement of multiple clinical programs.

Alpha Tau Medical maintains research and development operations in Rehovot, Israel, and U.S. offices in Houston, Texas, to support its global clinical development and regulatory activities. The company has secured the CE Mark in Europe for selected indications and is conducting multicenter trials in both Europe and the United States to expand its regulatory approvals. With a focus on partnerships and strategic collaborations, Alpha Tau Medical aims to integrate its alpha-therapy platform into standard-of-care regimens and broaden patient access to its treatments.